BeOne Medicines (NASDAQ:ONC) Director Corazon (Corsee) Sanders Sells 2,665 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Corazon (Corsee) Sanders sold 2,665 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $337.00, for a total value of $898,105.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

BeOne Medicines Stock Performance

BeOne Medicines stock opened at $351.13 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.72. The stock has a fifty day moving average price of $295.45 and a two-hundred day moving average price of $264.43. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $170.99 and a 52-week high of $351.27. The firm has a market capitalization of $38.48 billion, a P/E ratio of -202.96 and a beta of 0.21.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%.The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. As a group, analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 EPS for the current fiscal year.

Institutional Trading of BeOne Medicines

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ONC. Anchor Investment Management LLC acquired a new stake in BeOne Medicines in the second quarter worth about $26,000. Caitong International Asset Management Co. Ltd acquired a new stake in BeOne Medicines in the second quarter worth about $28,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines in the second quarter worth about $35,000. Farther Finance Advisors LLC acquired a new stake in BeOne Medicines in the second quarter worth about $39,000. Finally, Signaturefd LLC bought a new position in shares of BeOne Medicines in the 2nd quarter worth $49,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ONC. Morgan Stanley lifted their price objective on BeOne Medicines from $313.00 to $330.00 and gave the company an “overweight” rating in a research report on Friday, June 27th. JPMorgan Chase & Co. lifted their price objective on BeOne Medicines from $321.00 to $345.00 and gave the company an “overweight” rating in a research report on Thursday, July 17th. Royal Bank Of Canada lifted their price objective on BeOne Medicines from $349.00 to $364.00 and gave the company an “outperform” rating in a research report on Thursday, August 7th. Wall Street Zen downgraded BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. Finally, Guggenheim lifted their price objective on BeOne Medicines from $350.00 to $365.00 and gave the company a “buy” rating in a research report on Thursday, August 7th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, BeOne Medicines currently has a consensus rating of “Buy” and an average price target of $330.89.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.